WHO ICTRP trial
A study of stempeucel® in patients with critical limb ischemia due to occlusive…
CTRI/2018/02/011839 · Clinical Trials Registry India (CTRI) · Recruiting
Key facts
| Trial ID | CTRI/2018/02/011839 |
|---|---|
| Public title | A study of stempeucel® in patients with critical limb ischemia due to occlusive inflammatory condition of arteries and veins |
| Scientific title | An open label, multicenter Post Marketing Surveillance Study in India to assess safety and efficacy of Intramuscular administration of stempeucel® in patients with critical limb ischemia due to Buergerâ??s disease |
| Primary sponsor | Stempeutics Research Pvt Ltd |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Recruiting |
| Study type | PMS |
| Phase | Post Marketing Surveillance |
| Countries | India |
| Conditions | Health Condition 1: M622- Nontraumatic ischemic infarction of muscle |
| Interventions | Intervention1: Stempeucel®: Stempeucel® consists of ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells. Stempeucel® will be injected at a dose of 2 million cells/kg body weight intramuscularly once during the… |
| Registration date | Dec 2, 2018 |
| Target size | 200 |
| Secondary IDs | 0486-17, Version: 03, Date: 05/12/2017 |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: